This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
The objective was to compare ixabepilone plus capecitabine with capecitabine alone in patients with advanced breast cancer, who were resistant to taxanes and were previously treated with or resistant to an anthracycline.
Interventions
The interventions were ixabepilone 40mg per m 2 on day one, plus capecitabine 2g per m 2 per day for the first 14 days of each 21-day cycle, compared with capecitabine 2.5g per m 2 per day for the first 14 days of each 21-day cycle.
Location/setting
USA/secondary care.
Methods

Analytical approach:
A decision tree was used to model four levels of response to treatment, which were linked to survival curves for progression-free survival and overall survival. The survival data were from a single clinical study. The model had a lifetime horizon and the authors reported a health care system perspective.
Effectiveness data:
The clinical effectiveness data were from a randomised controlled trial that included women with locally advanced or metastatic breast cancer that was resistant to taxanes and had previously been treated with or was resistant to an anthracycline. After recruiting 377 patients the definition of taxane resistance was amended and a total of 752 patients were randomly assigned to treatment. The details of this study were reported elsewhere (Thomas, et al. 2007 , see 'Other Publications of Related Interest' below for bibliographic details).
Monetary benefit and utility valuations:
The utility estimates were applied to patients in four health states and were derived from the clinical trial. They were measured using the Health Utilities Index Mark 3 (HUI3). During active treatment, the utility values varied according to the treatment regimen and the level of response.
Measure of benefit:
The measure of benefit was quality-adjusted life-years (QALYs) gained and these were discounted at a rate of 3% per year, starting from the second month.
